
						
							
						
						
							<!--
							google_ad_client = "pub-5806585833518451";
							/* 300x250, created 6/2/09 - iposol_ipo_detail_top */
							google_ad_slot = "4379562531";
							google_ad_width = 300;
							google_ad_height = 250;
									-->
							
							
							
						

						Incorporated in 1993, Syngene International Ltd is a subsidiary of Biocon Limited ("Biocon"), a global biopharmaceutical enterprise focused on delivering affordable formulations and compounds.Headquartered in Bengaluru, Syngene International is India-based contract research organisations ("CRO"), offering a suite of integrated, end-to-end discovery and development services for novel molecular entities ("NMEs") across industrial sectors including pharmaceutical, biotechnology, agrochemicals, consumer health, animal health, cosmetic and nutrition companies. Their services in discovery and development cover multiple domains across small molecules, large molecules, antibody-drug conjugates ("ADC") and oligonucleotides.Syngene offer customized models as per their clients requirements. These range from a full-time equivalent ("FTE") to a fee-for-service ("FFS") model, or a combination thereof.  Till Dec 31, 2014, they serviced 195 clients, ranging from multinational corporations to start-ups, including seven of the top 10 global pharmaceutical companies by sales for 2014. Company's long term clients includes global healthcare organisations Bristol-Myers Squibb Co. ("BMS"), Abbott Laboratories (Singapore) Pte. Ltd. ("Abbott") and Baxter International Inc. ("Baxter").

						
						
							
						
						

						Company Promoters:Biocon Limited is the promoter of the company.

						Company Financials:
	ParticularsFor the year/period ended (in Rs. Million)
	31 Dec 1431 Mar 1431 Mar 1331 Mar 12
	Total Income6,1757,0775,5424,182
	Profit After Tax (PAT)1,1941,3481,021710


						
							<!--
								google_ad_client = "pub-5806585833518451";
								/* 300x250, created 9/3/09 - IPO Detail Center */
								google_ad_slot = "7910498455";
								google_ad_width = 300;
								google_ad_height = 250;
								-->
							
							
							
						

						Objects of the Issue:The objects of the offer are to:1. Achieve the benefits of listing the Equity Shares on the Stock Exchanges;2. Enhance visibility and brand image among existing and potential clients; and3. Provide liquidity to the existing shareholders.

						Issue Detail:
						  »»  Issue Open: Jul 27, 2015 - Jul 29, 2015
							  »»  Issue Type: Book Built Issue IPO
							  »»  Issue Size: 22,000,000 Equity Shares of Rs 10 aggregating up to Rs 550.00 Cr
							
							
							  »»  Face Value: Rs 10 Per Equity Share
							  »»  Issue Price: Rs. 240 - Rs. 250 Per Equity Share
							  »»  Market Lot: 60 Shares
							  »»  Minimum Order Quantity: 60 Shares
							  »»  Listing At: BSE, NSE
						

						


						
						Syngene International IPO Reviews:
						
							
							Syngene International Ltd IPO review by Dilip Davda
							
						
						


						
							
						

						
							Issue Subscription Detail / Current Bidding StatusNumber of Times Issue is Subscribed (BSE + NSE)As on Date & TimeQIBNIIRIIOthersTotalShares Offered / Reserved4,000,0003,000,0007,000,0002,000,00016,000,000Day 1 - Jul 27, 2015 17:00 IST0.50000.04000.47000.19000.3600Day 2 - Jul 28, 2015 18:00 IST1.22000.16001.41000.43001.0000Day 3 - Jul 29, 2015 18:10 IST51.470090.24004.78001.370032.0500
						
					
